

ATTORNEY DOCKET NO.: TNX 98-08-01

CUSTOMER NO: 26839

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

THOMAS, David, et al.)) Group Art Unit: 1614) Examiner: To Be Assigned)))
Serial No.: 09/810,883	
Filed: March 16, 2001	
For: BISPECIFIC MOLECULES CROSS- LINKING ITIM AND ITAM FOR THERAPY	

Assistant Commissioner for Patents Washington, D.C. 20231

Dear Sir:

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), applicants submit the documents listed on the attached PTO 1449. This Information Disclosure Statement is being filed within three months of the filing date of the above-referenced application. A fee of \$180.00 is attached.

Copies of the listed documents are attached. Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached PTO 1449 form.

This submission does not represent that a search has been made or that no other documents exist which may be material to the examination of this application and does not constitute an admission that any of the listed documents, or any part thereof, are material or constitute prior art under title 35 of the United States code. Applicants reserve the right to present evidence that any of such documents are not prior art.

06/20/2001 AZERGAW1 00000092 09810883

04 FC:126

180.00 OP

Appletion No.: 09/810,883 Attorney Docket No.: TNX 98-08-01 Customer No.: 26839

Applicant further reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

Respectfully Submitted,

Dated: June <u>15</u>, 2001.

Cheryl A. Liljestrand

Rég. No. 45,275